Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

KICK OUT 2: Study of a Karate Intervention to Change Kinematic Outcomes in Parkinson’s Disease

Clinical Trial Title: 
KICK OUT 2: A phase two, randomized, waitlist-controlled trial of a Karate Intervention to Change Kinematic OUTcomes in Parkinson’s disease.
Clinical Trial Protocol ID: 
18012313
Clinical Trial Investigator Name: 
Jori E. Fleisher, MD, MSCE
Clinical Trial Protocol Description: 

The purpose of this pilot study is to test whether and to what degree a community-based karate class tailored for individuals with early- to middle-stage Parkinson’s disease (PD) is feasible and improves objective and patient-reported outcomes compared with individuals given a standard exercise prescription for PD. Non-contact karate classes tailored to patients with Parkinson’s will be held at Chicago area dojos. We expect to recruit approximately 50 patients from Rush University Medical Center, other local hospital systems, senior centers, and local organizations.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are 30-90 years of age, male or female, and any race or ethnicity.
  • Have a diagnosis of early- to middle-stage Parkinson’s disease from a treating healthcare provider.
  • Are willing and able to commit to karate classes twice a week for 6-months.
  • Live in the Chicago area.

You will be excluded from the study if any of the following criteria apply to you:

  • Require an assistive device or the assistance of another person in order to ambulate.
  • Are unable to commit to attending two karate classes weekly for 6-months.
  • Have an atypical form of parkinsonism (such as progressive supranuclear palsy, multiple system atrophy, vascular parkinsonism, etc.) from a treating neurologist.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Parkinson's Disease and Other Movement Disorders
Contact Phone: 
(312) 563-2900 (Press 4/Code: Karate)
Contact Name: 
Jori Fleisher, MD MSCE